Please login to the form below

Not currently logged in
Email:
Password:

Merz Pharma appoints William Humphries as US CEO

He joins from GlaxoSmithKline company Stiefel

Merz Pharma Group has appointed a new leader for its North American business, selecting the former president of GlaxoSmithKline's Stiefel unit William Humphries.

As CEO of Merz's US business, Humphries will be based in Greensboro, North Carolina and takes charge of the company's medical dermatology global business unit.

He will also oversee the strategic direction of three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics and Merz Pharma Canada.

Merz Pharmaceuticals GmbH's CEO Dr Martin Zugel said: "Few people can match Bill's extensive knowledge across the pharmaceutical and aesthetic medicine categories. His knowledge, combined with his unparalleled experience as an innovative driver of organic and acquired expansion, brings a new era of leadership to the Merz companies.

"We are confident that Bill will lead our companies into a period of accelerated growth in the North American market."

Prior to joining Merz, Humphries served as president of Stiefel, during which time he spearheaded two major acquisitions and led the global integration of Stiefel into GlaxoSmithKline.

Before joining Stiefel, Humphries held a number of senior executive roles within Allergan, concluding as vicepresident of the US skincare business.

Humphries' appointment adds to a number of senior executive hires at Merz, including head of global business unit OTC/OTX and emerging markets Hans Regenauer and head of global business unit ethical pharma and regional head Western Europe Stefan Brinkmann.

15th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics